Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NBSE
3101
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $101K | ﹤0.01% |
168
+41
| +32% | +$43.3K |
|
3102
Actinium Pharmaceuticals
ATNM
$30.2M
| $100K | ﹤0.01% |
+3,818
| New | +$119K |
|
|
ACCS
3103
ACCESS Newswire
ACCS
$18.7M
| $98K | ﹤0.01% |
+10,900
| New | +$87.6K |
|
|
AXIA
3104
DELISTED
AXIA Energia
AXIA
| $97K | ﹤0.01% |
+17,932
| New | +$98.2K |
|
3105
IT Tech Packaging
ITP
$2.88M
| $97K | ﹤0.01% |
8,340
-470
| -5% | -$5.44K |
|
|
BYU
3106
DELISTED
BAIYU Holdings, Inc. Common Stock
BYU
| $97K | ﹤0.01% |
70
-1
| -1% | -$1.89K |
|
|
AIM
3107
AIM ImmunoTech
AIM
$7.17M
| $97K | ﹤0.01% |
32
-4
| -11% | -$16.1K |
|
|
AFMD
3108
DELISTED
Affimed
AFMD
| $92K | ﹤0.01% |
5,120
-2,290
| -31% | -$49.4K |
|
|
GPUS
3109
Hyperscale Data Inc
GPUS
$52.2M
| – | – |
0
| – | – |
|
|
EMXX
3110
DELISTED
Eurasian Minerals Inc
EMXX
| $92K | ﹤0.01% |
88,900
-21,400
| -19% | -$20.7K |
|
3111
Nortech Systems
NSYS
$35.6M
| $91K | ﹤0.01% |
23,300
+4,100
| +21% | +$15.7K |
|
|
QBAK
3112
DELISTED
Qualstar Corp
QBAK
| $91K | ﹤0.01% |
31,002
+3,600
| +13% | +$11.4K |
|
3113
RAVE Restaurant Group
RAVE
$44.2M
| $90K | ﹤0.01% |
47,900
+28,400
| +146% | +$67.9K |
|
3114
Nomura Holdings
NMR
$29.2B
| $89K | ﹤0.01% |
+15,100
| New | +$80.4K |
|
|
SSY
3115
DELISTED
SunLink Health Systems
SSY
| $89K | ﹤0.01% |
73,600
+8,200
| +13% | +$9.51K |
|
|
GNVC
3116
DELISTED
GenVec, Inc.
GNVC
| $89K | ﹤0.01% |
27,760
+9,310
| +50% | +$32.3K |
|
|
BSIN
3117
Big Sky Industrial
BSIN
$71.4M
| $88K | ﹤0.01% |
6,898
+430
| +7% | +$6.86K |
|
|
ACUR
3118
DELISTED
Acura Pharmaceuticals
ACUR
| $87K | ﹤0.01% |
113,220
+31,300
| +38% | +$32.7K |
|
3119
Eltek
ELTK
$57.1M
| $86K | ﹤0.01% |
21,880
+240
| +1% | +$1.12K |
|
3120
TROOPS Inc
TROO
$227M
| $86K | ﹤0.01% |
22,825
-900
| -4% | -$3.11K |
|
3121
Mexco Energy
MXC
$19.3M
| $85K | ﹤0.01% |
+17,000
| New | +$75.4K |
|
|
NLST
3122
DELISTED
Netlist, Inc.
NLST
| $84K | ﹤0.01% |
81,900
-165,700
| -67% | -$184K |
|
|
SDEV
3123
Stablecoin Development Corp
SDEV
$50.6M
| $83K | ﹤0.01% |
4
-2
| -33% | -$49.2K |
|
|
BIOL
3124
DELISTED
Biolase, Inc.
BIOL
| $83K | ﹤0.01% |
5
+2
| +67% | +$39.6K |
|
|
ATYR
3125
aTyr Pharma
ATYR
$54.2M
| $82K | ﹤0.01% |
2,721
-2,222
| -45% | -$91.1K |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.